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ABSTRACT: Liraglutide is a human glucagon-like peptide-1 (GLP-1) analogue approved for
the treatment of type 2 diabetes. It is based on human GLP-1 with the addition of a 16-carbon
fatty acid, which facilitates binding to plasma proteins, thus prolonging the elimination half-life
and allowing once-daily administration. It has not been possible to quantify liraglutide protein
binding by ultrafiltration (the usual method of choice), as the lipophilic molecule becomes
trapped in the filter membrane. Therefore, the aim of this study was to develop a methodology
that could determine the extent of liraglutide binding to plasma proteins in vitro. We report
here the details of a novel reiterated stepwise equilibrium dialysis assay that has successfully
been used to quantify liraglutide plasma protein binding. The assay allowed quantification of
liraglutide binding to proteins in purified plasma protein solutions and human plasma samples
and was effective at plasma dilutions as low as 5%. At a clinically relevant liraglutide concen-
tration (104 pM), greater than 98.9% of liraglutide was bound to protein. Specific binding to
human serum albumin and "1-acid glycoprotein was 99.4% and 99.3%, respectively. The novel
methodology described herein could have an application in the quantification of plasma pro-
tein binding of other highly lipophilic drug molecules. © 2013 Wiley Periodicals, Inc. and the
American Pharmacists Association J Pharm Sci 102:2882–2888, 2013
Keywords: liraglutide; type 2 diabetes mellitus; protein binding; plasma proteins; human
serum albumin; in vitro method; equilibrium dialysis; insulin detemir; acylated peptides
INTRODUCTION
Glucagon-like peptide-1 (GLP-1) is an incretin hor-
mone that induces glucose-dependent stimulation of
insulin and reduction in glucagon secretion, delays
gastric emptying and decreases appetite.1,2 Conse-
quently, there has been much interest in GLP-1 as
a treatment for type 2 diabetes. However, its ther-
apeutic application is limited by its rapid degrada-
tion by dipeptidyl peptidase-4 (DPP-4),3 resulting in
a half-life of approximately 1 h after subcutaneous
administration.4
Liraglutide is a human GLP-1 analogue designed
to provide a longer duration of action. The peptide
is linked via a (-L-glutamyl spacer to a 16-carbon
fatty acid residue.5 This facilitates reversible self-
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association and binding to serum albumin, slowing
release from the injection site and reducing degra-
dation by DPP-4, resulting in a plasma half-life of
approximately 13 h.6 Its apparent volume of distribu-
tion is low (11–17 L),6 approximating the distribution
volume of albumin, which is almost identical to the
total volume of blood and interstitial fluid (∼15 L),7
thus indicating high levels of plasma protein binding.
Plasma protein binding of a drug can be al-
tered by many factors, including disease state, age
and concomitant therapies. Hepatic impairment and
nephrotic syndrome, both of which are common
among patients with type 2 diabetes and the elderly,
are associated with hypoalbuminaemia,8 which could
potentially lead to altered protein binding levels of a
drug. Plasma protein binding of a drug is clinically im-
portant, as it can affect the predictability of its phar-
macokinetics, pharmacodynamics and dose–response
relationship.9 Plasma protein binding is critical to the
protracted duration of action of liraglutide; therefore,
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it is important to determine whether any of these con-
ditions alter liraglutide plasma protein binding.
Standard methods for determining drug binding
to plasma proteins include: in vivo measurements,
gel filtration, ultracentrifugation, ultrafiltration and
equilibrium dialysis. Ultrafiltration is the method of
choice for drugs that are not quickly degraded or
metabolised.10 However, it has previously been ob-
served that lipophilic drugs, such as liraglutide, in-
sulin detemir and other drugs with 16-carbon fatty
acid moieties, adsorb to the filter membrane rather
than passing through it.11 Initial attempts to quan-
tify plasma protein binding using standard equilib-
rium dialysis were also hindered by adsorption to the
dialysis membrane. To overcome this problem, we de-
veloped a hitherto unpublished reiterated stepwise
equilibrium dialysis method, which has been utilised
to measure the plasma protein binding of insulin
detemir.11
This methodology was later optimised to quantify
liraglutide plasma protein binding.12 Here, we de-
scribe the reiterated stepwise equilibrium dialysis
method, its validation and use to determine the extent
of in vitro binding of liraglutide to plasma proteins.
MATERIALS AND METHODS
All studies were performed according to good labora-
tory practice, and all reports formed part of the docu-
mentation submitted to the health authorities for the
approval of liraglutide.
Materials
Plasma was derived from ethylenediaminetet-
raacetic-acid-treated human blood, obtained under
fasting conditions from two male and two female
healthy volunteers who provided written in-
formed consent. Liraglutide [molecular weight (MW)
3.751 kg/mol] was obtained from Novo Nordisk A/S
(Bagsvaerd, Copenhagen, Denmark). Human serum
albumin (HSA) and "1-acid glycoprotein (AAGP) were
obtained from Sigma–Aldrich (Gillingham, UK).
Methods
Radiolabelling of Liraglutide and Stock Solution
Preparation
Liraglutide was radiolabelled to allow quantifica-
tion by liquid scintillation counting. [125/127I Tyr 19]-
labelled liraglutide was prepared and purified at the
Chemistry and Isotope Laboratory, Novo Nordisk A/S,
on the day before the dialysis incubation. Labelling
was performed by the lactoperoxidase/hydrogen
peroxide method, followed by purification and ra-
diochemical purity analysis by high-pressure liquid
chromatography as previously described.13 The ra-
diochemical stability of [125/127I Tyr 19]-labelled li-
raglutide was improved by diluting the Na[125I] 20-
fold with Na[127I] before iodination. This produced
a tracer with low specific activity (0.1:Ci/pmol) and
high radiochemical purity (>99%), which was main-
tained after 1 month at −20◦C.
Liraglutide stock solution (107 pM) comprised
3.8 mg liraglutide and 40:L iodinated liraglutide
(corresponding to 10:Ci/mL) in 100 mL Krebs–
Henseleit (KH) buffer (pH 7.4).14 Different liraglu-
tide concentrations were obtained (105 and 103 pM)
by serial dilution, as appropriate. Final liraglutide
concentrations of 106, 104 and 102 pM were obtained
by 1:10 dilution into plasma. A plasma-free buffer in-
cubation solution was also prepared.
Reiterated Stepwise Equilibrium Dialysis Assay
A standard equilibrium dialysis experimental set-up
is illustrated. Figures 1a and 1b show the modified
assay set-up, which was initiated with liraglutide in
both chambers to avoid it becoming trapped in the
dialysis membrane. Experiments were repeated at
different across-membrane liraglutide concentration
ratios (inner–outer) until liraglutide passage through
the dialysis membrane was minimal, indicating that
the system was at equilibrium.
The experimental set-up consisted of a Spectra/
Por R© Cellulose Ester Sterile DispoDialyzer sac (Spec-
trum Europe B.V., Breda, The Netherlands) contain-
ing 1.0 mL plasma (or HSA/AAGP) incubation solu-
tion with the appropriate concentration of liraglutide,
dependent on the across-membrane concentration ra-
tio required. Dialysis sacs had a diameter of 5 mm, a
declared inner volume of 1 mL (although only an ef-
fective volume of 0.7 mL can be drawn) and a MW
cut-off of 15 kDa, which provided the optimal bal-
ance between robustness and passage of the molecule.
Dialysis sacs were mounted in an outer chamber
filled with 12.5 mL buffer incubation solution, which
contained the appropriate concentration of liraglu-
tide in KH buffer. The outer chamber consisted of
a screw-capped Minisorb tube (catalogue #366060;
Nunc, Roskilde, Denmark), with an effective volume
of 15 mL. The outer chamber was pre-coated with li-
raglutide by incubating twice with buffer incubation
solution for 30 min at 37 ± 2◦C in a Memmert ther-
mostatic incubator (Memmert GmbH & Company KG,
Bu¨chenbach, Germany), followed by a final overnight
incubation. Forty-five millilitre of buffer incubation
solution (sufficient buffer for triplicate incubations)
was prepared in 50 mL screw-capped Minisorb tubes
(PBC catalogue #339497; Nunc).
Following pre-coating, dialysis sacs were mounted
into the outer buffer chambers and incubated at 37 ±
2◦C in a Memmert thermostatic incubator for 4–5 h
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Outer chamber:
15 mL pre-coated
Nunc minisorb tube
Inner chamber:
1 mL Spectra/Por® Cellulose
Ester Sterile DispoDialyzer sac
Buffer incubation solution
Buffer incubation solution
Dialysis membrane
Plasma incubation solution
Plasma incubation solution
Outer chamberInner chamber
Plasma protein Liraglutide molecule
a
b
Figure 1. The reiterated stepwise equilibrium dialysis assay. (a) Illustration of the experi-
mental set-up used to perform the assay; (b) schematic representation of the inner and outer
chamber buffer solutions at the start of the assay.
with mixing using an IKA-Schuttler MTS 2 electronic
mixer (IKA R©-Werke GmbH & Company KG, Staufen,
Germany) at the lowest step of horizontal rotation.
Experiments were performed in triplicate.
Sampling, Counting and Calculation of Binding Levels
After incubation, dialysis sacs were visually inspected
for yellow colouring of the outer buffer solution, indi-
cating invisible leakage. Extremely high radioactivity
counts were also the possible indicators of leakage.
Samples (0.7 mL) were extracted from inside the
dialysis sac, and 1 mL was extracted from the outer
chamber. Samples were counted for 10 min in a Wallac
1470 Wizard gamma counter (PerkinElmer, Waltham,
Massachusetts).
The percentage of the bound drug at equilibrium,
bound (%) was calculated as follows:
Bound (%) = [CPM/mL (inner) − CPM/mL (outer) ]
CPM/mL (inner)
× 100
where CPM is the counts per minute.
Results were calculated as the percentage of the
bound drug at equilibrium of concentration at pre-
incubation. Mean (standard deviation, SD) percent-
age of bound liraglutide was calculated from each
set of triplicate incubations using Excel (MicrosoftTM,
Seattle, Washington); results were rejected if the SD
was greater than 1.0.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 102, NO. 8, AUGUST 2013 DOI 10.1002/jps
IN VITRO PROTEIN BINDING OF LIRAGLUTIDE IN HUMAN PLASMA DETERMINED 2885
Reproducibility Testing
Reproducibility was confirmed by assessing intra- and
inter-day variation. To confirm stability of liraglu-
tide, a quantitative recovery was performed using
a liraglutide-specific enzyme-linked immunosorbent
assay (ELISA) (Capio Diagnostik A/S, Copenhagen,
Denmark) as described previously.15 Reproducibil-
ity assays were performed using undiluted plasma
pooled from all four volunteers and the plasma incu-
bation solution contained 104 pM liraglutide. Experi-
ments were performed at a liraglutide concentration
ratio of 100:1 (inner–outer). Intra-day variation was
evaluated in six assay runs performed on the same
day, whereas inter-day variation was assessed by as-
says performed on 5 separate days.
Liraglutide Plasma Protein Binding
The experiment was repeated with plasma incuba-
tion solutions containing 106, 104 (representing a clin-
ically relevant concentration)6 and 102 pM liraglu-
tide. Across-membrane inner–outer liraglutide ratios
of 100:1 and 50:1 (corresponding to 99% and 98%
liraglutide bound to plasma proteins, respectively)
were investigated, as studies had previously shown
close to 99% binding in human plasma.12 The effect of
diluting the plasma sample to 50%, 10% and 5% was
investigated at 104 pM liraglutide, and at both 100:1
and 50:1 inner–outer liraglutide ratios.
Liraglutide Binding to HSA and AAGP
The HSA incubation solution contained approxi-
mately 7.4 × 10−4 M (50 mg/mL) HSA (represent-
ing the physiological concentration in plasma)16 and
104pM liraglutide, diluted in KH buffer. Inner–outer
liraglutide ratios of 100:1 and 50:1 were used to inves-
tigate HSA binding (corresponding to 99% and 98%
bound, respectively).
"1-acid glycoprotein incubation solution contained
approximately 2.4 × 10−5 M (1 mg/mL) AAGP (repre-
senting the physiological concentration in plasma)17
and 104 pM liraglutide, diluted in KH buffer. AAGP
binding was assessed at liraglutide inner–outer ratios
of 2:1, 5:1, 10:1, 20:1, 50:1 and 100:1, corresponding
to 50%, 80%, 90%, 95%, 98% and 99%, respectively,
on the presumption that binding would be approxi-
mately 50% because of the results observed with other
acylated polypeptides (Plum, unpublished data).
Statistical Analyses
The arithmetic mean (SD) was calculated for each
concentration level and analysed using a two-sided
analysis of variance (ANOVA) for gender and concen-
tration effect. ANOVAs were performed using SAS
version 9.3 (SAS Institute Inc., Cary, North Carolina).
RESULTS
Reproducibility Testing
To confirm reproducibility, intra- and inter-day as-
say evaluations were performed (Table 1). The intra-
day coefficient of variation (CV) was 0.10%, and the
inter-day CV was 0.11%, demonstrating good repro-
ducibility. The mean (SD) concentration of liraglutide
recovered was 5883 (668) pM, as analysed by ELISA,
corresponding to 59% of the target concentration.
Liraglutide Plasma Protein Binding
The assay was used to determine the percentage
of circulating liraglutide that was bound to plasma
proteins in a previously published study.11 Results
from four healthy individuals are shown in Table 2.
At a clinically relevant concentration of 104 pM,6
98.7%–99.2% liraglutide was bound to protein.11 Di-
lution to 102 pM did not significantly affect protein
binding compared with 104 pM (estimated difference
0.05%; p = 0.581). When the concentration was in-
creased to 106 pM, protein binding was significantly
reduced compared with 104 pM (estimated difference:
−0.33%; p = 0.009) and 102 pM (estimated difference:
−0.38%; p = 0.0047). There was no significant effect
of gender on the proportion of protein-bound liraglu-
tide (estimated difference females vs. males: −0.18%;
p = 0.593). Furthermore, dilution of the plasma (50%
to 5%) did not affect the extent of liraglutide plasma
protein binding (Table 3).
Table 1. Intra- and Inter-Day Variation in Liraglutide Protein Binding
Intra-Day Mean (SD) Liraglutide Bound [%] Inter-Day Mean (SD) Liraglutide Bound [%]
Run 1 99.9 (0.03) Day 1 99.9 (0.03)
Run 2 99.7 (0.35) Day 2 99.8 (0.04)
Run 3 99.8 (0.06) Day 3 99.8 (0.04)
Run 4 99.9 (0.03) Day 4 99.8 (0.02)
Run 5 99.7 (0.22) Day 5 99.6 (0.19)
Run 6 99.8 (0.05)
Overall mean (SD) 99.8 (0.10) 99.8 (0.11)
Coefficient of variation (%) 0.10 0.11
Data are unadjusted means (SD).
Liraglutide concentration of the plasma incubation solution was 104 pM, and the inner–outer liraglutide ratio was 100:1.
The intra-day evaluation involved repetition of the assay six times in 1 day, whereas the inter-day assay involved repetition of the assay on 5 separate days.
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Table 2. Extent of Liraglutide Protein Binding in Plasma Collected from Healthy Volunteers
Mean (SD) Liraglutide Bound [%]
Liraglutide Concentration
of the Plasma Incubation Buffer (pM) Male 1 Male 2 Female 1 Female 2
Inner–outer ratio (100:1)
106 99.0 (0.5) 98.6 (0.3) 99.0 (0.2) 98.3 (0.4)
104 99.2 (0.5) 99.2 (0.5) 99.1 (0.3) 98.7 (0.6)
102 99.3 (0.3) 99.0 (0.5) 99.3 (0.5) 98.8 (0.4)
Inner–outer ratio (50:1)
106 98.4 (0.9) 97.6 (0.5) 98.6 (0.3) 97.3 (0.3)
104 99.4 (0.1) 98.2 (0.2) 98.9 (0.8) 97.0 (0.8)
102 99.2 (0.2) 99.1 (0.2) 99.2 (0.1) 97.9 (1.0)
Data are unadjusted means (SD)
Table 3. Effect of Plasma Dilution on Percentage of Liraglutide
Bound to Plasma Proteins
Mean (SD) Liraglutide Bound [%]
Plasma (%)
Inner–Outer Ratio
(50:1)
Inner–Outer Ratio
(100:1)
100 99.4 (0.1) 99.2 (0.5)
50 98.8 (0.5) 99.3 (0.3)
10 99.2 (0.1) 99.2 (0.5)
5 99.3 (0.0) 99.5 (0.3)
Data are unadjusted means (SD). Liraglutide concentration of the
plasma incubation buffer was 104 pM.
Liraglutide Binding to HSA and AAGP
Human serum albumin is the most abundant protein
in human plasma,18 whereas AAGP is a plasma gly-
coprotein that is elevated in some disease states.19
In order to quantify HSA and AAGP binding of li-
raglutide, the assay was performed using physiolog-
ical concentrations of HSA and AAGP (50 and 1 mg/
mL, respectively).17 At a liraglutide concentration of
104 pM, and inner–outer ratio of 100:1, more than
99% of liraglutide was bound to HSA and AAGP
(Table 4).
Table 4. Liraglutide Binding to Human Serum Albumin and
"1-acid Glycoprotein Across a Range of Inner–Outer Liraglutide
Ratios
Mean (SD) Liraglutide Bound
[%]
Inner–Outer Ratio (%) HSA AAGP
1:1 (50) n/p 55.7 (3.8)
5:1 (80) n/p 83.8 (1.0)
10:1 (90) n/p 93.0 (0.1)
20:1 (95) n/p 96.9 (0.1)
50:1 (98) 99.0 (0.0) 98.7 (0.1)
100:1 (99) 99.4 (0.1) 99.3 (0.0)
Data are unadjusted means (SD). Liraglutide concentration of the
plasma incubation buffer was 104 pM.
n/p, not performed.
DISCUSSION
The present study describes a novel assay that can be
used to quantify the proportion of liraglutide bound
to plasma proteins in vitro. It was used to determine
a previously reported finding12 that at a clinically rel-
evant liraglutide concentration of 104 pM,6 approxi-
mately 99% of liraglutide was bound to plasma pro-
teins. Protein binding was significantly reduced at a
higher concentration of liraglutide (106 pM), but the
absolute difference was small (0.4%) and unlikely to
be clinically relevant, given that 106 pM is approxi-
mately 50-fold higher than steady-state levels in hu-
mans. Gender had no apparent effect on binding, al-
though this should be interpreted with caution given
the small sample size. The extent of liraglutide pro-
tein binding was not affected by dilution of the plasma
sample to 5% concentration. Liraglutide was highly
bound to both HSA and AAGP.
As with many plasma-protein-bound drugs, only
the unbound fraction of liraglutide interacts with the
effector to produce a pharmacological response.19 This
assay showed that 98%–99% of liraglutide was bound
to plasma proteins.12 Therefore, at a clinically rele-
vant liraglutide concentration (104 pM), the unbound
liraglutide concentration would be 100–200 pM,
which is in accordance with the half maximal effec-
tive concentration value for liraglutide.5 If the extent
of plasma protein binding of a drug becomes altered,
then it can affect the volume of distribution and rate
of clearance.9
The effect of reduced plasma protein levels on li-
raglutide protein binding is of clinical relevance. Hep-
atic impairment is common among people with type
2 diabetes and often results in reduced levels of HSA.
In a pharmacokinetic study of liraglutide in patients
with hepatic impairment, the lowest level of HSA
was 3 × 10−4 M (∼20 mg/mL),12 20-fold higher than
that in the 5% plasma solution [∼1.5 × 10−5 M (1 mg/
mL)] analysed herein. This indicates that hepatic
impairment is unlikely to reduce liraglutide plasma
protein binding. Furthermore, physiological levels of
HSA and AAGP (∼10−3 and 10−5 M, respectively) are
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1000- to 10,000-fold higher than clinically relevant
concentrations of liraglutide; therefore, the reduced
plasma protein levels observed in hepatic impair-
ment are unlikely to affect liraglutide binding. In-
deed, in the pharmacokinetic study of Flint et al.12,
the unbound fraction of liraglutide was very low in
all groups, with no clear association with hepatic im-
pairment. At a liraglutide concentration of 102 pM,
mean (SD) unbound percentages were 0.53% (0.46)
in healthy subjects, as compared with 0.59% (0.61),
0.68% (0.45) and 0.40% (0.2) in those with mild, mod-
erate and severe hepatic impairment, respectively.12
Renal impairment is another common condition
associated with type 2 diabetes that can result in
marked hypoalbuminaemia.8 Reassuringly, liraglu-
tide pharmacokinetics was not altered in a study of
subjects with mild-to-severe renal impairment versus
healthy subjects.20
The lipophilic nature of 16-carbon fatty acylated
peptides such as liraglutide can make it difficult
to quantify plasma protein binding by ultrafiltra-
tion, as they can become trapped within the filter
membrane.11 The methodology reported herein rep-
resents a novel approach to quantify liraglutide pro-
tein binding in vitro. Inclusion of liraglutide in the
plasma/protein incubation solution, as well as in the
buffer incubation solution, prevented the lipophilic
molecule from becoming trapped in the dialysis mem-
brane. Furthermore, pre-coating of the chamber with
liraglutide prevented the loss of the drug through ad-
sorption to the surface of the chamber. Together, these
modifications allowed the measurement of liraglutide
binding to plasma proteins with good reproducibility.
The dialysis sac volume used in this assay is rela-
tively large (1 mL); therefore, when considering the
small volumes of plasma that are normally obtained
from patient populations, the ability to dilute sam-
ples to 5% in this assay was advantageous. However,
dilution should be performed with reference to the
albumin status of patients and the plasma concentra-
tions of the drug.
The high level of plasma protein binding demon-
strated in this study is part of the mechanism through
which liraglutide’s plasma half-life is extended. Its
prolonged duration of action ensures that constant
exposure is achieved with once-daily dosing. As type
2 diabetes patients have a blunted GLP-1 response,
it is likely that the constant exposure of liraglutide is
important for its efficacy. The GLP-1 receptor agonist
exenatide does not demonstrate significant levels of
plasma protein binding and has a shorter duration
of action, necessitating twice-daily administration.21
This may help to explain the greater glycaemic ef-
ficacy achieved with liraglutide compared with exe-
natide.
CONCLUSIONS
The reiterated stepwise equilibrium dialysis assay de-
scribed herein is suitable for the in vitro quantifica-
tion of liraglutide protein binding. The assay has been
used to quantify the high plasma protein binding lev-
els of liraglutide (∼99%),12 a property that underlies
its prolonged duration of action. The high physiolog-
ical levels of plasma proteins relative to liraglutide
indicate that its binding is unlikely to be affected in
conditions associated with lower albumin levels, such
as hepatic impairment. In the future, this assay could
be used to determine the effect of other highly plasma-
protein-bound drugs on liraglutide plasma protein
binding. The methodology could also have applica-
tions in determining the plasma protein binding of
other lipophilic drug molecules that are unsuitable
for ultrafiltration.
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